Chai Discovery
Biotech
Chai Discovery is a venture-backed AI biotech company that builds generative models for de novo antibody design. This generative antibody design process compresses the antibody discovery cycle from 12 to 24 months to four to eight weeks. Its flagship Chai-2 model achieved 20% experimental hit rates across 52 de-novo designed targets, a 200x improvement over prior computational methods. Founded in March 2024 by a team with roots in OpenAI and Absci, the company has gained traction both with its open-source Chai-1 structure prediction model and its pharmaceutical partnership with Eli Lilly.
Full Memo
In-depth resources
From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development
Chai’s the Limit for AI Antibody Designer After $130M Series B Funding
Our Investment in Chai Discovery
I Tried to Poke Holes in Chai-2’s Antibody Design Paper. Here’s What I Found.
AI Bio Expert: 99% Faster Drug Discovery, BioTech’s AlphaGo Moment, Building Photoshop for Molecules
Revolutionizing Antibody Design with AI: Why We’re Backing Chai Discovery
No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier
Zero-shot antibody design in a 24-well plate
Chai-1: Decoding the molecular interactions of life
A primer on machine learning in antibody engineering
© 2024 Contrary Research · All rights reserved
Privacy Policy